具体内容详见公司同日在巨潮资讯网（www.cninfo.com.cn）上披露的 《2025 年第三季度报告》。 第六届董事会第七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、 董事会会议召开情况 江苏华兰药用新材料股份有限公司（以下简称"华兰股份"或"公司"）第 六届董事会第七次会议通知于 2025 年 10 月 15 日以邮件、电话等方式向各位董 事发出，会议于 2025 年 10 月 21 日以现场会议结合通讯形式召开。本次会议由 公司董事长华一敏先生召集并主持，应出席会议的董事 9 人，实际出席会议的 董事 9 人，其中肖锋先生、崔珂女士、姚茗芳女士、单体超先生、陈岗先生、 刘力先生、侯绪超先生以通讯表决方式出席本次董事会会议，公司高级管理人 员列席了会议。本次会议的召集、召开及表决符合《公司法》等有关法律、法 规、规范性文件和《公司章程》的规定，会议合法、有效。 二、 董事会会议审议情况 1、会议以 9 票同意、0 票反对、0 票弃权，审议通过了《关于<2025 年第 三季度报告>的议案》。 证券代码：301093 证券简称：华兰 ...

Core Insights - Hualan Co., Ltd. reported a revenue of 441 million yuan for the first three quarters of 2025, representing a year-on-year growth of 4.36% [1] - The net profit attributable to shareholders of the listed company was 53.316 million yuan, showing a year-on-year increase of 2.06% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 40.826 million yuan, reflecting a year-on-year growth of 13.66% [1] - The basic earnings per share stood at 0.325 yuan [1]

Core Viewpoint - Hualan Co., Ltd. announced the convening of its sixth board meeting to review the third quarter report for 2025, indicating ongoing corporate governance and financial oversight [1] Company Summary - Hualan Co., Ltd. reported that for the first half of 2025, 99.07% of its revenue came from the pharmaceutical manufacturing sector, while other businesses contributed only 0.93% [1] - As of the report, Hualan Co., Ltd. has a market capitalization of 6.5 billion yuan [1]

Core Viewpoint - Hualan Co., Ltd. reported a revenue of 441 million yuan for the first three quarters of 2025, reflecting a year-on-year growth of 4.36% [1] - The net profit attributable to shareholders reached 53.32 million yuan, marking a year-on-year increase of 2.06% [1] - The net profit after deducting non-recurring gains and losses was 40.83 million yuan, showing a year-on-year growth of 13.66% [1] - Basic earnings per share stood at 0.325 yuan [1] Financial Performance - Revenue for the first three quarters: 441 million yuan, up 4.36% year-on-year [1] - Net profit attributable to shareholders: 53.32 million yuan, up 2.06% year-on-year [1] - Net profit after non-recurring items: 40.83 million yuan, up 13.66% year-on-year [1] - Basic earnings per share: 0.325 yuan [1]

Core Insights - The company reported a third-quarter revenue of 132 million yuan, representing a year-on-year decline of 4.72% [1] - The net profit for the third quarter was 9.58 million yuan, down 37.20% year-on-year [1] - For the first three quarters, the company achieved a revenue of 441 million yuan, which is a year-on-year increase of 4.36% [1] - The net profit for the first three quarters was 53.32 million yuan, reflecting a year-on-year growth of 2.06% [1] Financial Performance - Third-quarter revenue: 132 million yuan, down 4.72% year-on-year [1] - Third-quarter net profit: 9.58 million yuan, down 37.20% year-on-year [1] - Year-to-date revenue (first three quarters): 441 million yuan, up 4.36% year-on-year [1] - Year-to-date net profit (first three quarters): 53.32 million yuan, up 2.06% year-on-year [1]

Financial Performance - The company's revenue for Q3 2025 was CNY 132,482,970.99, a decrease of 4.72% compared to the same period last year[4] - Net profit attributable to shareholders was CNY 9,583,905.64, down 37.20% year-on-year[4] - The basic earnings per share (EPS) was CNY 0.0587, reflecting a decline of 35.92% compared to the previous year[4] - Total operating revenue for the current period reached ¥441,244,733.57, an increase of 4.3% compared to ¥422,796,240.46 in the previous period[24] - Net profit for the current period was ¥53,228,184.49, slightly higher than ¥52,237,238.79 from the previous period, indicating a growth of 1.9%[25] - The total comprehensive income for the period was CNY 53,203,987.60, compared to CNY 52,237,238.79 in the previous period, reflecting an increase[26] - Basic and diluted earnings per share increased to CNY 0.325 from CNY 0.312, representing a growth of 4.2%[26] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,517,621,152.73, an increase of 0.51% from the end of the previous year[4] - The company's total assets increased to ¥2,517,621,152.73 from ¥2,504,747,738.80, marking a growth of 0.5%[22] - Current assets totaled ¥1,696,410,418.59, a marginal increase from ¥1,694,546,494.58, showing a growth of 0.1%[21] - The total liabilities increased to ¥339,410,297.54 from ¥255,985,703.16, reflecting a rise of 32.5%[22] - The company's equity attributable to shareholders decreased to ¥2,173,815,374.04 from ¥2,245,764,811.04, a decline of 3.2%[23] Cash Flow - Cash flow from operating activities showed a net decrease of 38.84%, totaling CNY 76,392,286.01[4] - Cash flow from operating activities generated a net amount of CNY 76,392,286.01, down from CNY 124,903,079.59 in the previous period, indicating a decline of 38.7%[26] - Cash inflow from investment activities totaled CNY 2,749,626,741.19, compared to CNY 1,868,199,767.22 in the previous period, marking an increase of 47%[27] - The net cash flow from investment activities was CNY 81,506,737.58, up from CNY 49,966,552.03, showing a growth of 63.2%[27] - Cash flow from financing activities resulted in a net outflow of CNY 5,302,493.58, an improvement from a net outflow of CNY 304,706,045.98 in the previous period[27] - The ending balance of cash and cash equivalents increased to CNY 530,608,277.75 from CNY 278,556,876.99, reflecting a growth of 90.5%[27] Investments and Income - Investment income decreased by 63.73% to CNY 4,837,039.94 due to reduced returns from cash management products[11] - The company’s cash management income increased significantly, contributing to a fair value change gain of CNY 8,603,831.56, up 121.91% year-on-year[11] - The company received CNY 2,727,000,000.00 from the recovery of investments, significantly higher than CNY 1,822,960,000.00 in the previous period, indicating a growth of 49.7%[27] Shareholder Information - The total number of common shareholders at the end of the reporting period was 13,278, with no preferred shareholders having restored voting rights[14] - The largest shareholder, Jiangyin Hualan Electromechanical Technology Co., Ltd., holds 22.39% of shares, totaling 36,764,000 shares[14] - The top ten shareholders collectively hold significant stakes, with the second-largest shareholder, Ruizhong Life Insurance Co., Ltd., holding 16.38% or 26,901,579 shares[14] - The company has a total of 2,975,699 shares held in its repurchase special securities account, accounting for 1.81% of the total share capital[16] - The company plans to unlock shares held by executives and other stakeholders according to the established schedule, with significant amounts set for release in May 2025[18] Operating Costs and Expenses - Total operating costs amounted to ¥393,422,388.46, up from ¥380,153,962.71, reflecting a rise of 3.3%[24] - Research and development expenses for the current period were ¥29,541,151.81, compared to ¥28,885,335.31 in the previous period, indicating an increase of 2.3%[24] - Cash paid for dividends, profits, or interest decreased by 67.39% to $25,312,311.97, reflecting a reduction in cash dividends distributed[13] - Cash paid for other financing activities decreased by 52.96% to $108,243,481.61, due to a reduction in the implementation of share repurchases[13]

Market Performance - The medical device sector increased by 1.01% on October 21, with Botao Bio leading the gains [1] - The Shanghai Composite Index closed at 3916.33, up 1.36%, while the Shenzhen Component Index closed at 13077.32, up 2.06% [1] Top Gainers - Botao Bio (688767) closed at 43.39, up 8.12% with a trading volume of 50,200 shares and a transaction value of 216 million [1] - Xiangsheng Medical (688358) closed at 34.93, up 6.62% with a trading volume of 45,600 shares and a transaction value of 157 million [1] - Hualan Biological (301093) closed at 39.30, up 6.53% with a trading volume of 57,500 shares and a transaction value of 223 million [1] Top Losers - Jinhao Medical (920925) closed at 31.85, down 2.24% with a trading volume of 11,900 shares and a transaction value of 37.83 million [2] - Toukeng Life (300642) closed at 26.75, down 2.01% with a trading volume of 162,300 shares and a transaction value of 44.4 million [2] - Maillande (688273) closed at 40.48, down 1.99% with a trading volume of 22,300 shares and a transaction value of 90.15 million [2] Capital Flow - The medical device sector experienced a net outflow of 229 million from institutional investors and 168 million from retail investors, while retail investors saw a net inflow of 397 million [2][3] - Notable capital inflows included Xinhua Medical with a net inflow of 24.93 million from institutional investors [3] - Hualan Biological had a net inflow of 20.37 million from institutional investors, despite a net outflow from retail investors [3]

证券代码：301093 证券简称：华兰股份 公告编号：2025-104 江苏华兰药用新材料股份有限公司 关于 2025 年员工持股计划第一次持有人会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、 持有人会议召开情况 江苏华兰药用新材料股份有限公司（以下简称"公司"）2025 年员工持股 计划第一次持有人会议（以下简称"本次会议"）于 2025 年 10 月 17 日以通讯 方式召开。 本次会议由公司副总经理、董事会秘书刘雪女士召集和主持，会议出席持 有人 225 人，代表 2025 年员工持股计划持有人持有股份数 2,783,132 股，占 2025 年员工持股计划有表决权股份总数的 97.68%。本次会议的通知、召开和表 决程序符合相关法律法规及公司 2025 年员工持股计划的有关规定，会议所作决 议合法有效。 二、 持有人会议审议情况 （一）审议通过《关于设立公司 2025 年员工持股计划管理委员会的议案》 为保证公司 2025 年员工持股计划的顺利实施，保障持有人的合法权益，根 据公司《2025 年员工持股计划（草案）》《2025 年员 ...

Group 1 - The core point of the news is that Hualan Co., Ltd. experienced a decline of 5.14% in its stock price, reaching 34.51 CNY per share, with a total market capitalization of 5.667 billion CNY [1] - Hualan Co., Ltd. is primarily engaged in the research, production, and sales of packaging materials for injectable drugs, with its main revenue sources being film-coated rubber stoppers (49.07%) and conventional rubber stoppers (48.50%) [1] - The company was established on June 4, 1992, and went public on November 1, 2021 [1] Group 2 - From the perspective of major fund holdings, one fund under Dacheng Fund has a significant position in Hualan Co., Ltd., with 620,000 shares held, accounting for 3.29% of the fund's net value [2] - The Dacheng Growth Mixed Fund (160926) has reported a floating loss of approximately 1.1594 million CNY due to the decline in Hualan's stock price [2] - The fund has achieved a year-to-date return of 25.68% and a one-year return of 27.96%, ranking 3506 out of 8160 and 3478 out of 8021 respectively in its category [2]

Key Recommendations - The report highlights the social services industry, particularly focusing on the chain restaurant sector, recommending leading brands that offer good value for money in the dining and tea beverage segments [7] - The construction industry report emphasizes the necessity of cleanroom engineering as a critical component of AI infrastructure, with global demand for construction rapidly increasing [11] Industry and Company Insights - In the restaurant sector, the report notes that in September 2025, the stock prices of major restaurant brands faced pressure, with notable increases for brands like Xiaobai Xiaobai (+33%) and Yum Brands (+4%) [7] - The mid-year financial summary indicates that the tracked chain restaurant leaders saw a 29% increase in net profit attributable to shareholders in the first half of 2025, with a 16% revenue growth, outperforming the overall retail dining market growth of 4% [7] - The cleanroom engineering market is driven by the need for controlled environments in precision product manufacturing, with investments in cleanroom engineering typically accounting for 10-20% of total project costs [11] - The global cleanroom market is expected to grow due to increasing demands for semiconductor manufacturing and data center construction, particularly in North America, which is identified as a market with significant potential [11] Market Dynamics - The report indicates that in September 2025, the domestic restaurant revenue showed a slight year-on-year increase of 1%, recovering from previous months' declines [7] - The cleanroom engineering demand is expected to rise as companies like TSMC ramp up investments in the U.S., with TSMC planning an additional $100 billion investment, indicating a robust growth trajectory for the cleanroom sector [11] Investment Recommendations - The report suggests focusing on leading companies in the cleanroom engineering space, such as Shenghui Integration and Yaxiang Integration, which are expected to benefit from the global semiconductor supply chain restructuring [12] - In the restaurant sector, it recommends investing in brands like Xiaobai Xiaobai, Gu Ming, and Mi Xue Group, which are positioned to capitalize on the recovery and growth in the dining market [9]